Divi's Laboratories Limited

BSE: 532488 NSE: DIVISLAB
Divi's Laboratories Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L24110TG1990PLC011854 Incorporated 12 October 1990 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: DIVISLAB · BSE: 532488 Public Limited Company pharma Fortune India 500 · #271 Nifty 500
Market Cap
₹3,01,758 Cr
DIVISLAB · NSE
Share Price
₹11,485.00
+1.04% today
Revenue
₹10,560 Cr
FY 2025-26 · +12.8% YoY
EBITDA
₹3,368 Cr
Margin 31.9%
Net Profit
₹2,623 Cr
FY 2025-26 · +19.7% YoY
P/E (TTM)
89.9x
P/B 17.1x
ROE
16.2%
ROCE 21.0%
Authorised capital
₹60 Cr
Registered with MCA

About Divi's Laboratories Limited

Data last updated:

Divi's Laboratories Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 12 October 1990 and has been in existence for over 36 years.

Divi's Laboratories is ranked #271 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director Murali Divi and family are #13 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24110TG1990PLC011854. Its GSTIN is 36AAACD6745J1ZH (Telangana). The company holds 6 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 532488 and NSE: DIVISLAB.

The company has an authorised share capital of ₹60 Cr and a paid-up capital of ₹53.09 Cr. It was formerly known as Divi'S Research Centre Private Limited and Divi'S Laboratories Private Limited. It is led by directors including Murali Krishna Prasad Divi (Managing Director) and Nimmagadda Venkata Ramana (Whole-Time Director).

Its last annual general meeting (AGM) was held on 10 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 1 – 72/23(P)/Divis/303 Divi Towers Cyber Hills Gachibowli, Hyderabad, Telangana, India – 500032.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹10,560 Cr, a growth of 12.8% compared to the previous year. For the same year it recorded a net profit of ₹2,623.04 Cr (net margin 24.8%) and EBITDA of ₹3,368 Cr (EBITDA margin 31.9%). The net worth stands at ₹16,761 Cr (up 12% YoY). Total assets are valued at ₹17,523 Cr (up 17% YoY).

The company has about 11,560 employees on its provident fund (EPFO) records.

The company is associated with 2 brands: Divis Nutraceuticals and Divis Laboratories. As per MCA filings, the company has open charges of ₹5 Cr and satisfied charges of ₹1,186.72 Cr on record. Court records list 56 cases involving the company, including 24 filed by the company and 32 filed against it; 26 cases are pending. The company has 51 deals on record (51 market trades); the latest was in October 2025. Its 7 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations) are compared by revenue, 4 larger and 3 smaller; the largest is Cipla Limited with revenue of ₹28,409 Cr. The company has 1 MSME Form 1 return on record for the period ending Sep 2019, listing 2 overdue payments to 1 micro and small supplier.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website divislabs.com.

Company details

CIN L24110TG1990PLC011854
Registration Number 011854
Incorporation Date 12 October 1990
ROC Hyderabad
Listing Status Listed - Listed on NSE (DIVISLAB); Listed on BSE (532488)
Company Status Active
Compliance Status Active Compliant

Name history

Divi's Laboratories has undergone 2 name changes throughout its history. The company was previously known as Divi's Research Centre Private Limited, and Divi's Laboratories Private Limited. The current legal name is Divi'S Laboratories Limited.

Company NameStatus
Divi's Laboratories LimitedCurrent
Divi's Research Centre Private LimitedPrevious
Divi's Laboratories Private LimitedPrevious

CIN history

Divi's Laboratories has one previous CIN (Corporate Identification Number): L24110AP1990PLC011854. The current CIN is L24110TG1990PLC011854, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24110TG1990PLC011854Current
L24110AP1990PLC011854Previous
Key People
Murali Krishna Prasad Divi Managing Director Nimmagadda Venkata Ramana Whole-Time Director Satchandra Kiran Divi Whole-Time Director

Recognitions & Rankings of Divi's Laboratories

Fortune India 500 2025 edition
Rank#271
Total income
₹9,808 Cr
Profit
₹2,191 Cr
Last year #285
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#39
Valuation
₹1,58,220 Cr
2023 #46 2022 #41 2021 #33
India's Richest People 2026 edition · 1 director · Source: Hurun India
Stock market indices
Nifty 500 BSE 500

Contact details

Divi's Laboratories Limited's registered office is in Hyderabad, Telangana. Its website is divislabs.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    divislabs.com
  • Social Media
  • Registered Address
    1 – 72/23(P)/Divis/303 Divi Towers Cyber Hills Gachibowli, Hyderabad, Telangana, India – 500032
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Divi's Laboratories Limited, buy the company report.

Comprehensive company report
Divi's Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Divi's Laboratories operates two associated brands: Divis Nutraceuticals and Divis Laboratories. Each brand links to its own profile.

BrandDescriptionWebsite
Divis Nutraceuticals
Manufacture of carotenoid and vitamin ingredients for food, beverage, and nutrition industries.divisnutraceuticals.com
Divis Laboratories
Contract manufacturer of APIs, intermediates, and building blocks of peptides and nucleotidesdivislabs.com

Business activity

The main business activity of Divi's Laboratories is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Divi's Laboratories Limited, buy the company report.

Financials of Divi's Laboratories Limited

FY 2025-26 filings available

Divi's Laboratories Limited reported revenue of ₹10,560 Cr (up 12.8% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹10,560 Cr
+12.8% YoY
EBITDA
₹3,368 Cr
+13.4% YoY
Profit After Tax
₹2,623 Cr
+19.7% YoY
Net Worth
₹16,761 Cr
+12.0% YoY
Total Assets
₹17,523 Cr
+17.0% YoY
Total Debt
₹7.00 Cr
+75.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10,5609,3607,8457,7688,9606,9695,394
Revenue growth+12.8%+19.3%+1.0%-13.3%+28.6%+29.2%-
EBITDA3,3682,9692,2062,3693,8832,8611,823
EBITDA margin+31.9%+31.7%+28.1%+30.5%+43.3%+41.1%+33.8%
Profit before tax3,3882,9162,1632,3693,6842,6661,819
Net profit2,6232,1911,6031,8242,9621,9871,335
Net profit margin+24.8%+23.4%+20.4%+23.5%+33.1%+28.5%+24.8%
EPS (₹)96.9182.6860.3868.69111.5374.7551.86
Balance sheet
Total assets17,52314,97313,61112,80111,7599,3257,369
Net worth16,76114,96913,57112,76711,7289,2957,310
Total debt7.004.003.003.263.694.8338.85
Cash & bank3,4143,7153,9804,2132,8192,156123
Net working capital9,0558,6318,3988,2117,1575,0632,816
Cash flow
Cash from operations2,7381,6531,2612,4601,9121,9471,216
Cash from investing(2,219)(804)(269)(2,708)(2,195)75.13(83.47)
Cash from financing(804)(799)(799)(797)(532)(34.89)(1,091)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3,6763,0802,8312,6042,7152,4102,5852,319
Revenue growth (YoY)+35.4%+27.8%+9.5%+12.3%+16.1%+13.8%--
Other income94.0064.0015588.0014511986.0082.00
EBITDA1,5661,255934816888729886743
EBITDA margin+42.6%+40.7%+33.0%+31.3%+32.7%+30.2%+34.3%+32.0%
Depreciation14213312011811311210799.00
Interest13.006.006.006.008.003.001.000.00
Profit before tax1,5051,180963780912733864726
Tax378278212197223188202137
Net profit1,127902751583689545662589
EPS (₹)42.4933.9528.3121.9825.9720.4924.9322.20
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10,3889,1987,6657,6258,8806,7995,311
Revenue growth+12.9%+20.0%+0.5%-14.1%+30.6%+28.0%-
EBITDA3,4152,9802,1752,3493,8782,8221,816
EBITDA margin+32.9%+32.4%+28.4%+30.8%+43.7%+41.5%+34.2%
Profit before tax3,4362,9292,1322,3543,6772,6281,813
Net profit2,6622,2091,5751,8052,9501,9571,331
Net profit margin+25.6%+24.0%+20.6%+23.7%+33.2%+28.8%+25.1%
EPS (₹)98.3883.3659.4768.23111.0873.6451.71
Balance sheet
Total assets17,46614,89713,52112,73611,7189,2977,371
Net worth16,71114,89513,48412,70511,6919,2727,317
Total debt0.002.000.000.000.000.3533.63
Cash & bank3,3713,6963,9614,1882,8042,142107
Net working capital9,0158,5618,3138,1577,1285,0372,821
Cash flow
Cash from operations2,7111,6501,2662,4471,9101,9471,208
Cash from investing(2,218)(803)(268)(2,707)(2,195)75.34(81.38)
Cash from financing(802)(797)(798)(796)(532)(33.97)(1,091)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3,6472,9742,7932,5782,6602,3572,5362,297
Revenue growth (YoY)+37.1%+26.2%+10.1%+12.2%+15.6%+14.3%--
Other income88.0063.0015487.0014611987.0082.00
Total expenses2,0601,7341,8501,7451,7651,6141,6551,550
EBITDA1,5871,240943833895743881747
EBITDA margin+43.5%+41.7%+33.8%+32.3%+33.6%+31.5%+34.7%+32.5%
Depreciation14213212011611311210799.00
Interest13.006.006.006.008.003.000.000.00
Profit before tax1,5201,165971798920747861730
Tax380274215200224190194136

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 12 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3,6763,0802,8312,6042,7152,4102,5852,319
Revenue growth (YoY)+35.4%+27.8%+9.5%+12.3%+16.1%+13.8%--
Other income94.0064.0015588.0014511986.0082.00
EBITDA1,5661,255934816888729886743
EBITDA margin+42.6%+40.7%+33.0%+31.3%+32.7%+30.2%+34.3%+32.0%
Depreciation14213312011811311210799.00
Interest13.006.006.006.008.003.001.000.00
Profit before tax1,5051,180963780912733864726
Tax378278212197223188202137
Net profit1,127902751583689545662589
EPS (₹)42.4933.9528.3121.9825.9720.4924.9322.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10,5609,3607,8457,7688,9606,9695,394
Revenue growth+12.8%+19.3%+1.0%-13.3%+28.6%+29.2%-
Other income50735233934511462.56190
Total expenses7,1926,3915,6395,3985,0774,1083,571
Employee cost1,4421,2431,094975946826621
EBITDA3,3682,9692,2062,3693,8832,8611,823
EBITDA margin+31.9%+31.7%+28.1%+30.5%+43.3%+41.1%+33.8%
Depreciation463402378343312256186
Interest24.003.004.001.962.002.107.14
Profit before tax3,3882,9162,1632,3693,6842,6661,819
Tax820725563545723682443
Net profit2,6232,1911,6031,8242,9621,9871,335
Net profit margin+24.8%+23.4%+20.4%+23.5%+33.1%+28.5%+24.8%
EPS (₹)96.9182.6860.3868.69111.5374.7551.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital53.0053.0053.0053.0953.0953.0953.09
Reserves & surplus16,70814,91613,51812,71411,6759,2427,257
Shareholders' funds (net worth)16,76114,96913,57112,76711,7289,2957,310
Minority interest0.000.000.000.000.000.000.00
Secured loans0.002.000.000.000.000.3533.63
Unsecured loans7.002.003.003.263.694.485.22
Total debt7.004.003.003.263.694.8338.85
Total liabilities17,52314,97313,61112,80111,7599,3257,369
Assets
Gross block9,4137,8686,7606,3655,6244,6923,514
Net block6,5285,4424,7394,7234,3253,7042,782
Capital work in progress2,1131,022778212470711920
Investments69.0065.0082.0077.0572.010.01971
Inventories3,9543,2363,1843,0002,8292,1451,864
Sundry debtors2,9842,7312,1561,7932,4241,6771,413
Cash & bank balances3,4143,7153,9804,2132,8192,156123
Loans & advances744399355306280197309
Total current assets11,09610,0819,6759,3128,3526,1753,708
Total current liabilities2,0411,4501,2771,1011,1951,111892
Net working capital9,0558,6318,3988,2117,1575,0632,816
Total assets17,52314,97313,61112,80111,7599,3257,369
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash4133631701,2152,03043.152.10
Net cash from operating activities2,7381,6531,2612,4601,9121,9471,216
Net cash from investing activities(2,219)(804)(269)(2,708)(2,195)75.13(83.47)
Net cash from financing activities(804)(799)(799)(797)(532)(34.89)(1,091)
Net change in cash(285)50.00193(1,045)(816)1,98741.05
Closing cash3,4143,7153,9804,2132,8192,156123
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.8%+19.3%+1.0%-13.3%+28.6%+29.2%-
EBITDA growth+13.4%+34.6%-6.9%-39.0%+35.7%+56.9%-
PBT growth+16.2%+34.8%-8.7%-35.7%+38.2%+46.5%-1.9%
Net income growth+19.7%+36.7%-12.1%-38.4%+49.1%+48.8%-
Revenue CAGR (3Y)+10.8%+1.5%+4.0%+12.9%+21.9%+21.4%+9.9%
EBITDA CAGR (3Y)+12.4%-8.6%-8.3%+9.1%+27.5%+31.3%+8.0%
Profitability & leverage
Net income margin+24.3%+23.4%+20.4%+23.5%+33.0%+28.5%+25.5%
Return on capital employed+21.0%+20.4%+16.4%+19.3%+35.0%+32.0%+25.3%
Return on net worth+16.2%+15.4%+12.2%+14.9%+28.2%+23.9%+19.3%
Debt / equity0.000.000.000.000.000.000.01
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.830.120.220.100.060.080.44
Efficiency & per share
Fixed asset turnover1.221.281.201.301.741.701.75
Inventory turnover2.942.922.542.673.603.482.97
Debtors turnover3.703.833.973.684.374.514.19
EPS (₹)96.9182.6860.3868.69111.5374.7551.86
Dividend per share (₹)30.0030.0030.0030.0030.0020.0016.00
Book value per share (₹)632.49564.87512.11480.96441.82350.15275.38
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3,6472,9742,7932,5782,6602,3572,5362,297
Revenue growth (YoY)+37.1%+26.2%+10.1%+12.2%+15.6%+14.3%--
Other income88.0063.0015487.0014611987.0082.00
Total expenses2,0601,7341,8501,7451,7651,6141,6551,550
EBITDA1,5871,240943833895743881747
EBITDA margin+43.5%+41.7%+33.8%+32.3%+33.6%+31.5%+34.7%+32.5%
Depreciation14213212011611311210799.00
Interest13.006.006.006.008.003.000.000.00
Profit before tax1,5201,165971798920747861730
Tax380274215200224190194136
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10,3889,1987,6657,6258,8806,7995,311
Revenue growth+12.9%+20.0%+0.5%-14.1%+30.6%+28.0%-
Other income50635233734911162.53190
Total expenses6,9736,2185,4905,2765,0023,9773,494
Employee cost1,4001,2101,067953927809608
EBITDA3,4152,9802,1752,3493,8782,8221,816
EBITDA margin+32.9%+32.4%+28.4%+30.8%+43.7%+41.5%+34.2%
Depreciation461401376342311255186
Interest24.002.004.002.001.731.817.03
Profit before tax3,4362,9292,1322,3543,6772,6281,813
Tax829720556546728673441
Net profit2,6622,2091,5751,8052,9501,9571,331
Net profit margin+25.6%+24.0%+20.6%+23.7%+33.2%+28.8%+25.1%
EPS (₹)98.3883.3659.4768.23111.0873.6451.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital53.0053.0053.0053.0053.0953.0953.09
Reserves & surplus16,65814,84213,43112,65211,6389,2187,264
Shareholders' funds (net worth)16,71114,89513,48412,70511,6919,2727,317
Secured loans0.002.000.000.000.000.3533.63
Unsecured loans0.000.000.000.000.000.000.00
Total debt0.002.000.000.000.000.3533.63
Total liabilities17,46614,89713,52112,73611,7189,2977,371
Assets
Gross block9,3977,8596,7526,3585,6184,6853,508
Net block6,5205,4404,7374,7194,3213,6992,776
Capital work in progress2,1131,022778212470711920
Investments76.0072.0089.0084.0079.377.37979
Inventories3,7113,0332,9852,7812,6442,0431,744
Sundry debtors3,2282,8552,2731,9642,5701,7461,533
Cash & bank balances3,3713,6963,9614,1882,8042,142107
Loans & advances724395353303278195305
Total current assets11,0349,9799,5729,2368,2966,1253,690
Total current liabilities2,0191,4181,2591,0791,1681,089869
Net working capital9,0158,5618,3138,1577,1285,0372,821
Total assets17,46614,89713,52112,73611,7189,2977,371
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3943441441,2002,01627.88(7.96)
Net cash from operating activities2,7111,6501,2662,4471,9101,9471,208
Net cash from investing activities(2,218)(803)(268)(2,707)(2,195)75.34(81.38)
Net cash from financing activities(802)(797)(798)(796)(532)(33.97)(1,091)
Net change in cash(309)50.00200(1,056)(817)1,98835.84
Closing cash3,3713,6963,9614,1882,8042,142107
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.9%+20.0%+0.5%-14.1%+30.6%+28.0%-
EBITDA growth+14.6%+37.0%-7.4%-39.4%+37.4%+55.4%-
PBT growth+17.3%+37.4%-9.4%-36.0%+39.9%+44.9%-1.1%
Net income growth+20.5%+40.2%-12.7%-38.8%+50.7%+47.0%-
Revenue CAGR (3Y)+10.9%+1.2%+4.1%+12.8%+22.1%+21.2%+9.7%
EBITDA CAGR (3Y)+13.3%-8.4%-8.3%+9.0%+28.0%+31.1%+8.1%
Profitability & leverage
Net income margin+25.1%+24.0%+20.6%+23.7%+33.2%+28.8%+25.9%
Return on capital employed+21.4%+20.6%+16.3%+19.3%+35.0%+31.6%+25.2%
Return on net worth+16.5%+15.6%+12.0%+14.8%+28.1%+23.6%+19.2%
Debt / equity0.000.000.000.000.000.000.01
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.810.080.220.100.050.070.43
Efficiency & per share
Fixed asset turnover1.201.261.171.271.721.661.73
Inventory turnover3.083.062.662.813.793.593.12
Debtors turnover3.423.593.623.364.124.153.77
EPS (₹)98.3883.3659.4768.23111.0873.6451.71
Dividend per share (₹)30.0030.0030.0030.0030.0020.0016.00
Book value per share (₹)630.60562.08508.83479.43440.44349.28275.63

To see the full year-wise statements and ratios of Divi's Laboratories Limited, buy the company report.

Board of directors of Divi's Laboratories Limited

Divi's Laboratories has 10 current directors and 12 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sunaina Singh
Also directs: Veljan Denison Limited
Director28 Mar 20197 Years 7 MonthsCurrent
Rameshbabu Venkata NimmagaddaDirector27 Jun 20179 Years 4 MonthsCurrent
Murali Krishna Prasad Divi
Also directs: Divi's Biotech Private Limited, Divi's Properties Private Limited, Divi's Resorts and Agro Farms Private Limited
Managing Director12 Oct 199036 Years 1 MonthsCurrent
Nimmagadda Venkata Ramana
Also directs: Maarrc Padmini Real Yield LLP
Whole-Time Director01 Oct 199432 Years 1 MonthsCurrent
Satchandra Kiran Divi
Also directs: Divi's Biotech Private Limited, Divi's Properties Private Limited, Divi's Resorts and Agro Farms Private Limited and 2 more
Whole-Time Director10 Aug 200125 Years 3 MonthsCurrent
Nilima Prasad Divi
Also directs: Divi's Biotech Private Limited, Divi's Properties Private Limited, Divi's Resorts and Agro Farms Private Limited and 3 more
Whole-Time Director27 Jun 20179 Years 4 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Peer comparison

Divi's Laboratories Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Cipla Limited₹28,409 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Lupin Limited₹22,904 Cr (FY 2025)14.0%Mumbai, Maharashtra, India
Hetero Labs Limited₹16,537 Cr (FY 2025)13.0%Hyderabad, Telangana, India
Divi's Laboratories Limitedthis company₹10,560 Cr (FY 2026)₹2,623.04 Cr24.8%12.8%Hyderabad, Telangana, India
Biocon Biologics Limited₹10,144 Cr (FY 2025)13.0%Bengaluru, Karnataka, India
Ipca Laboratories Limited₹9,032.39 Cr (FY 2025)15.0%Mumbai, Maharashtra, India
Emcure Pharmaceuticals Limited₹7,963.26 Cr (FY 2025)19.0%Pune, Maharashtra, India
Mylan Laboratories Limited₹7,503.56 Cr (FY 2025)-23.0%Hyderabad, Telangana, India

To see the full peer comparison of Divi's Laboratories Limited, buy the company report.

Auditor

Divi's Laboratories Limited is audited by Price Waterhouse Chartered Accountants LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
Price Waterhouse Chartered Accountants LLPFY 2025012754N/N500016

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 51.90%, foreign institutional investors hold 20.20%, domestic institutional investors hold 19.40% and retail and other public shareholders hold 8.50%.

Promoters: 51.90%DII (Domestic Institutional): 19.40%FII (Foreign Institutional): 20.20%Retail & Others: 8.50%
Sep 2026
QUARTER
51.90% Promoters
19.40% DII (Domestic Institutional)
20.20% FII (Foreign Institutional)
8.50% Retail & Others
Promoter holding - history
Now 51.90% · Sep 2026High 51.90% · Dec 2025Low 51.90% · Dec 2025
50%50.8%51.5%52.3%53%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 51.90%Mar 2026: 51.90%Jun 2026: 51.90%Sep 2026: 51.90%51.90%51.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters51.90%51.90%51.90%51.90%
Public48.10%48.10%48.10%48.10%

Charges & borrowings

Open charges
₹5 Cr
Satisfied charges
₹1,186.72 Cr
Breakdown by lending institutions
Industrial Development Bank of India₹5.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
06 Feb 200090138180Industrial Development Bank of India₹5 CrOpen
27 Feb 2019100246839Hdfc Bank Limited₹60.5 CrSatisfied
28 Oct 200610024113The Bank of Nova Scotia₹20.9 CrSatisfied
15 Jun 200610009667State Bank of India - Overseas Branch₹50.58 CrSatisfied
28 Dec 200580001506Bank of Nova Scotia₹20 CrSatisfied

To see the full charge records of Divi's Laboratories Limited, buy the company report.

Total charge records: 27 View all charges

Deals & funding

Divi's Laboratories Limited has 51 deals on record (51 market trades); the latest was in October 2025.

Total deals
51
Market trades
51

Deals on record (5 of 51)

WhenDealAmountParties
Oct 2025Market trade₹20.26 CrBuyer: Goldman Sachs Bank Europe Se - Odi
Seller: Goldman Sachs (Singapore) Pte - Odi
Jul 2025Market trade₹14.95 CrBuyer: The Mtbj Ltd.As Trst For Government Pension Investment Fund Mtbj400045849
Seller: The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mtbj400045828
Nov 2024Market trade₹48.03 CrBuyer: Pi Opportunities Aif V LLP
Seller: Premjiinvest
Oct 2023Market trade₹15.82 CrBuyer: Northern Lights Fund Trust Iii Rondure New World Fund
Seller: Rondure New World Fund
May 2007Market trade₹33.14 CrBuyer: P R B Securities Pvt Ltd
Seller: P R B Securities Pvt Ltd

To see the full deal history of Divi's Laboratories Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Divi's Laboratories Limited was last rated by Care on 05 Oct 2021.

Rating agencyRated onRating
Care05 Oct 2021

To see the full credit ratings and regulatory alerts of Divi's Laboratories Limited, buy the company report.

MSME payment delays

Divi's Laboratories Limited has 1 MSME Form 1 return on record for the period ending Sep 2019, listing 2 overdue payments to 1 micro and small supplier. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (1 of 1)

SupplierAmount dueDue sinceReported on
Economy Process Solutions Private Limited

To see the full MSME payment records of Divi's Laboratories Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

GST

Divi's Laboratories has 6 GST registrations: 6 active. The first 4 active GSTINs are listed below.

Total GSTINs
6
Active
6
GSTINStateStatusRegistered on
36AAACD6745J1ZHTelanganaActive01 Jul 2017
36AAACD6745J3ZFTelanganaActive01 Mar 2019
37AAACD6745J1ZFAndhra PradeshActive01 Jul 2017
37AAACD6745J2ZEAndhra PradeshActive06 Jul 2017

To see the full GST registrations and return filing status of Divi's Laboratories Limited, buy the company report.

Recent activity

Divi's Laboratories Limited has 21 board changes on record since 1990: 10 appointments and 11 cessations. The latest: Kishore Babu Lingamneni ceased to be CFO on 01 Aug 2025.

AGM
Divi'S Laboratories Limited last Annual general meeting of members was held on 10 Aug 2026 as per latest MCA records.
Filing
Divi'S Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Charges
A charge registered on 27 Feb 2019 via Charge ID 100246839 with Hdfc Bank Limited was fully satisfied on 07 Feb 2026.
Charges
A charge registered on 14 Dec 1995 via Charge ID 90137808 with State Bank Of India was fully satisfied on 31 Jan 2026.
Ceased
Kishore Babu Lingamneni ceased to be CFO.
Appointed
Rajendra Kumar Premchand was appointed as Director.
Ceased
Gangavarapu Suresh Kumar ceased to be Director.
Appointed
Devendra Rao Sureddy was appointed as Whole-Time Director.
Ceased
Madhusudana Rao Divi ceased to be Whole-Time Director.
Charges
A charge with State Bank Of India of Rs. 454.50 Cr registered on 14 Dec 1995 with Charge ID 90137808 was modified on 07 Apr 2022.
Charges
A charge with Hdfc Bank Limited of Rs. 60.50 Cr registered on 27 Feb 2019 with Charge ID 100246839 was modified on 10 Mar 2022.
Appointed
Veerayya Chowdary Kosaraju was appointed as Director.

88 earlier events are in the company report.

News

DIVISLAB: RS. 57.54 CRORES NSE BLOCK TRADE; FOR ~ 50,581 SHARES, AT RS. 11375.00
11 Nov 2026 · Exchange Update
Divi's Labs: Management Confirms Double-Digit Revenue Growth Outlook For The Second Half Of FY2027, While Not Specifying A More Exact Percentage Beyond The 17% Constant Currency Growth Seen In The First Half.
09 Nov 2026 · Exchange Update
DIVISLAB: Q2 EBITDA 15.66B RUPEES VS 8.88B (YOY); Q2 EBITDA MARGIN 42.60% VS 32.71% (YOY)
07 Nov 2026 · Exchange Update
DIVISLAB: Q2 CONS NET PROFIT 11.27B RUPEES VS 6.89B (YOY) || Q2 REVENUE 36.76B RUPEES VS 27.15B (YOY)
07 Nov 2026 · Exchange Update
DIVISLAB: RS. 63.94 CRORES BSE BLOCK TRADE; FOR ~ 72,121 SHARES, AT RS. 8865.00
23 Oct 2026 · Exchange Update
DIVISLAB: RS. 90.52 CRORES NSE BLOCK TRADE; FOR ~ 99,986 SHARES, AT RS. 9053.00
22 Oct 2026 · Exchange Update

From our blog

Frequently asked questions

Divi's Laboratories is an active public limited company based in Hyderabad, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 12 October 1990 (36+ years old) and is registered under CIN L24110TG1990PLC011854. Listed on BSE: 532488 and NSE: DIVISLAB.

Divi's Laboratories reported revenue of ₹10,560 Cr for FY 2025-26 (up 12.8% YoY) based on consolidated financials.

Divi's Laboratories has 10 current directors:

The latest financial statements of Divi's Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 10 August 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Divi's Laboratories is 36AAACD6745J1ZH, registered in Telangana. The company has 6 GST registrations in all, of which 6 are active. Other active GSTINs include 36AAACD6745J3ZF (Telangana), 37AAACD6745J1ZF (Andhra Pradesh), 37AAACD6745J2ZE (Andhra Pradesh).

The CIN (Corporate Identification Number) of Divi's Laboratories is L24110TG1990PLC011854. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Divi's Laboratories is a listed company as per MCA records. Its shares are listed on both BSE (code: 532488) and NSE (symbol: DIVISLAB).

Divi's Laboratories has 56 court cases on record: 24 filed by the company and 32 filed against it. 26 are pending. Most are in the high courts.

Divi's Laboratories was incorporated on 12 October 1990, making it 36+ years old. It is registered with the Registrar of Companies, Hyderabad.

Divi's Laboratories has 51 deals on record (51 market trades); the latest was in October 2025.

The peers of Divi's Laboratories by revenue are Cipla Limited, Lupin Limited, Hetero Labs Limited, Biocon Biologics Limited, Ipca Laboratories Limited and 2 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).

Kishore Babu Lingamneni ceased to be CFO on 01 Aug 2025. Rajendra Kumar Premchand was appointed as Director on 25 May 2024. Gangavarapu Suresh Kumar ceased to be Director on 31 Mar 2024. Divi's Laboratories has 21 board changes on record in total.